The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OFIX | +1.25% | -51.52% | -13.48% | +55% |
| S&P | +14.5% | +93.32% | +14.09% | +1,538% |
Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.
The company had a big leadership change after an investigation.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $203.12M | 2.3% |
| Gross Profit | $135.66M | 4.0% |
| Gross Margin | 66.79% | 1.1% |
| Market Cap | $436.87M | -12.2% |
| Market Cap / Employee | $0.27M | 0.0% |
| Employees | 1.6K | -1.1% |
| Net Income | -$14.08M | 57.9% |
| EBITDA | $0.11M | 101.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $68.69M | 138.0% |
| Accounts Receivable | $129.56M | 3.3% |
| Inventory | 173 | -17.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $200.89M | 36.5% |
| Short Term Debt | $3.85M | -58.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.39% | -0.9% |
| Return On Invested Capital | -10.91% | -2.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.74M | 1642.9% |
| Operating Free Cash Flow | $11.38M | 26.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.13 | 1.27 | 1.25 | 0.95 | 9.36% |
| Price to Sales | 0.77 | 0.85 | 0.79 | 0.54 | -16.67% |
| Price to Tangible Book Value | 2.64 | 2.95 | 3.00 | 2.39 | 26.70% |
| Enterprise Value to EBITDA | -437.68 | 150.48 | -51.25 | 5490.33 | -6796.68% |
| Return on Equity | -20.9% | -22.9% | -27.8% | -24.6% | 21.24% |
| Total Debt | $156.17M | $193.71M | $192.76M | $204.74M | 30.96% |
OFIX earnings call for the period ending September 30, 2021.
OFIX earnings call for the period ending June 30, 2021.
OFIX earnings call for the period ending March 31, 2021.
OFIX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
